Having raised $100mn Intrexon in-licenses Halozyme's technology for A1AT
This article was originally published in Scrip
Executive Summary
Under a deal potentially worth $63 million, Halozyme Therapeutics has granted the licensing rights for its recombinant human hyaluronidase enzyme (rHuPH20) technology to privately-held Intrexon, for use in the development of a subcutaneous injectable formulation of Intrexon's recombinant human alpha 1-antitrypsin (rHhA1AT).